about
Exploiting order effects to improve the quality of decisionsA measurement framework for adherence in patient decision aid trials applied in a systematic review subanalysis.Exclusion Criteria in National Health State Valuation Studies: A Systematic Review.Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysisExploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues.Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision application) for 'nudging' patients towards high quality decisions.Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.Surgical assessment: measuring unobserved health.Multiple treatment comparison meta-analyses: a step forward into complexity.The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis.An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE studyA Time Trade-off-derived Value Set of the EQ-5D-5L for CanadaMaking smart investment decisions in clinical researchBinary choice health state valuation and mode of administration: head-to-head comparison of online and CAPIThe efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.Attitude to health risk in the Canadian population: a cross-sectional survey.Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study.Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.Health state utility values: a description of their development and application for rheumatic diseases.The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritisObesity and overweight in Canada: an updated cost-of-illness study.A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.Measuring and valuing productivity loss due to poor health: A critical review.Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.An update on the measurement of productivity losses due to rheumatoid diseases.The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.Impact of inflammatory bowel disease on disability.Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement.How important is mode of administration in treatments for rheumatic diseases and related conditions?The effect of OSA on work disability and work-related injuries.Physician attitudes toward shared decision making: A systematic review.The cost-effectiveness of patient decision aids: A systematic review.Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review.Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment.Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments.
P50
Q29397742-03C5A7CF-2DB8-4BD1-B3D5-D35D510B7016Q30250294-7E58B11E-B2F2-48AA-9976-99CC9660412FQ30252110-3C7B5801-F1BA-4061-8790-0643F02100A5Q31031757-E176575D-1C40-4977-A7D0-1CB53D9FE982Q33422129-2CFB984C-C082-4D8B-9D85-CEEA6097A96AQ33692177-1DABAAD7-4E7E-4D10-B521-A70872360B8FQ33818374-DCB9A3BC-800B-4172-BAF5-EAD4E5D6A027Q34033150-C3B6FE44-C5BB-404B-A495-F08010CD389DQ34157292-AE7FB5D6-F01D-455F-9295-8C300E17FBB1Q34346259-FE9B2B7B-9628-4CAC-87B6-1552607BE35CQ35074243-3E78A643-B75B-4FD0-8022-E72DB3E30EA1Q35089776-471F45D2-9D62-468F-B69F-B08BA7046783Q35571598-B6218029-C1B1-413D-9768-D5857C1A4421Q36055449-52030321-1531-4448-9C51-3964FED82E13Q36183792-38EBAB28-25E9-4EAF-B65F-BA31121AD6F4Q36358903-48689701-3CCB-4655-84C2-A14E0A14F4B8Q36409914-8A0CF8AA-D362-4683-9172-183E0E188E10Q36567135-36E0677C-B3A1-4303-A6CA-7B933AC1EB1BQ36810833-5AE42D40-B70D-405F-B9EC-C09720E2CCF2Q37066921-7B5ADDAD-2BA1-40F9-8E9F-67AA8D170D86Q37101040-FFC89C46-8857-424F-A332-5BF612437326Q37144969-7C56E09F-7C56-4E3B-8B97-470E7B09D20DQ37199171-4F71F709-5318-4138-811D-014AA564669EQ37387224-5462FF77-6923-4E32-B5D4-1E2B9CD2B945Q37469260-E7BA0F84-AB8E-49E8-A007-79BEE871E0E6Q37609399-16AA08F3-17DD-412A-BB1C-6E393C4CFEA7Q37819249-5A2C00D8-A3B2-42A5-B6BD-3760D7575113Q37848117-71764178-4316-4897-A834-096320CFACD6Q38065443-4A43DD08-63F8-4825-A633-B074C1DB8CF6Q38065449-E259803A-A8E2-45FE-ADAC-77B2DE0DD9DCQ38251199-5B6174F4-4885-4773-81C2-C564B8EB1D23Q38376987-7BFAD5F6-BE09-436F-9AEA-AFB9D2245E32Q38436502-A7B72EBA-E4F8-4B69-92F9-310B03FBDF18Q38458465-A8CA2236-011F-4641-ABF7-1903D86D2A79Q38542154-7554A7AC-65F7-4A37-AEE4-66A9E38C7915Q38562131-D083D98A-0216-435A-B0EC-3F2AFF1B7CAEQ38628314-D1BE39A4-AC7E-4B53-8D40-B4B23DC5324BQ38650525-ACEB4A93-6D5D-4BD2-95A8-F2D16C371275Q38656874-AEBCC327-A48F-4FC4-BE0E-B0A12E122AC4Q38682667-2581C281-8B54-4195-AE9F-304472417F75
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nick Bansback
@ast
Nick Bansback
@en
Nick Bansback
@es
Nick Bansback
@nl
Nick Bansback
@sl
type
label
Nick Bansback
@ast
Nick Bansback
@en
Nick Bansback
@es
Nick Bansback
@nl
Nick Bansback
@sl
prefLabel
Nick Bansback
@ast
Nick Bansback
@en
Nick Bansback
@es
Nick Bansback
@nl
Nick Bansback
@sl
P106
P1153
55971305900
P21
P31
P496
0000-0002-1510-3462